Cardeon AB
NNGM:CARDEO0.05
SEK
-0.01
(-18.18%)
ISIN
SE0020050896
Return %
Stock
S&P 500
1Y
-12.90
14.20
3Y
-60.29
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Masoud Khayyami
- Sector
- Finance
- Industry
- Financial conglomerates
- Address
- Lund Sweden
- IPO Date
- Apr 13, 2018
- Website
- cardeon.se
- Similar Companies
- Business
- Cardeon AB (publ) (NGM: CARDEO) is a Sweden-based investment company that focuses on growth investments in early-stage Nordic companies and startups within medical technology and life science. The company provides active ownership support, including financing strategies, network access for partnerships and key recruitments, and board expertise to advance research ideas into commercial products; its portfolio comprises both listed and unlisted holdings such as SpectraCure AB (photodynamic therapy systems for solid tumors including prostate cancer), Lumito AB (imaging technology for tissue diagnostics), Prolight Diagnostics AB (point-of-care testing platforms like Psyros for biomarker detection), NeoDynamics AB (NeoNavia biopsy systems for cancer diagnostics), Neola Medical AB (NEOLA lung monitoring for preterm infants), TEQCool AB (selective brain cooling for neurological fever), Reccan Diagnostics AB (biomarker platforms for pancreatic and solid tumor cancer), NanoEcho (magneto-acoustic ultrasound for rectal cancer imaging), CarryGenes Therapeutics (synthetic chromosome gene therapies for advanced cancers), Cellestia Biotech (transcription factor inhibitors for oncology and autoimmune diseases), and Deep Light Vision (ultrasound optical tomography for organ oxygenation imaging). Cardeon invests primarily in the Nordic region, targeting innovative solutions with global market disruption potential in oncology, diagnostics, and medtech; operations span Sweden and emphasize diversified exposure across development stages from pre-clinical to commercialization. Founded in 2018 and headquartered in Lund, Sweden, the company resulted from a 2022 merger with Tectona Capital AB, with shares listed on NGM Nordic SME since November 2022. Recent developments include a February 2024 acquisition of 19% in Deep Light Vision for SEK 6 million; a Q1 2024 rights issue of units raising approximately SEK 16.6 million net to fund portfolio growth; planned dividend of TEQCool shares (46% of holding, valued at SEK 17.8 million book value) proposed for 2024 AGM; AcroPharma strategic alliances and patent filings in 2025; Prolight's European patents, preclinical data, and UK pilots in 2025; TEQCool market strategy updates and leadership changes; and Reccan Diagnostics selection for an EU project in June 2025, alongside ongoing clinical milestones in portfolio companies like SpectraCure.